Detalhe da pesquisa
1.
Decoding myofibroblast origins in human kidney fibrosis.
Nature
; 589(7841): 281-286, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33176333
2.
A new alternative: inhibiting complement activation in patients with IgA nephropathy.
Kidney Int
; 105(1): 28-30, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38182298
3.
Factor XI inhibition in hemodialysis patients: the safer anticoagulation?
Kidney Int
; 106(1): 21-23, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38906653
4.
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis.
Kidney Int
; 105(1): 31-34, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38182299
5.
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis.
Kidney Int
; 105(3): 447-449, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38388147
6.
The role of desmoglein-2 in kidney disease.
Kidney Int
; 105(5): 1035-1048, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38395410
7.
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
Kidney Int
; 105(6): 1306-1315, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38552841
8.
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lancet
; 402(10405): 859-870, 2023 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591292
9.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Lancet
; 402(10417): 2077-2090, 2023 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37931634
10.
Reduction of Endothelial Glycocalyx on Peritubular Capillaries in Chronic Kidney Disease.
Am J Pathol
; 193(2): 138-147, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36414084
11.
Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and Hypoglycemia.
Am J Kidney Dis
; 83(1): 18-27, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37657634
12.
Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.
Nephrol Dial Transplant
; 39(4): 569-580, 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38341276
13.
Interactive exploration of adverse events and multimorbidity in CKD.
Nephrol Dial Transplant
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38664006
14.
Identifying individuals at risk of needing CKD associated medications in a European kidney disease cohort.
BMC Nephrol
; 25(1): 60, 2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38378456
15.
The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis.
J Am Soc Nephrol
; 34(2): 241-257, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36351762
16.
Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD.
J Am Soc Nephrol
; 34(6): 955-968, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36918388
17.
IgA nephropathy: the lectin pathway and implications for targeted therapy.
Kidney Int
; 104(2): 254-264, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37263354
18.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Kidney Int
; 103(2): 391-402, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36270561
19.
International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology.
Kidney Int
; 104(1): 36-45, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37001557
20.
DNA binding protein YB-1 is a part of the neutrophil extracellular trap mediation of kidney damage and cross-organ effects.
Kidney Int
; 104(1): 124-138, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36963487